U-Neuron Biomedical Inc

TPEX:6973 Stock Report

Market Cap: NT$1.2b

U-Neuron Biomedical Valuation

Is 6973 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 6973 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 6973's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 6973's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 6973?

Key metric: As 6973 is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 6973. This is calculated by dividing 6973's market cap by their current book value.
What is 6973's PB Ratio?
PB Ration/a
BookNT$0
Market CapNT$1.16b

Price to Book Ratio vs Peers

How does 6973's PB Ratio compare to its peers?

The above table shows the PB ratio for 6973 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average3.7x
6610 TWi Biotechnology
4.8xn/aNT$1.2b
4131 NeoCore Technology
3.9xn/aNT$1.2b
6814 Lukas Biomedical
3.3xn/aNT$1.2b
4117 General Biologicals
2.7xn/aNT$1.1b
6973 U-Neuron Biomedical
n/an/aNT$1.2b

Price-To-Book vs Peers: Insufficient data to calculate 6973's Price-To-Book Ratio vs. peers for valuation analysis.

Price to Book Ratio vs Industry

How does 6973's PB Ratio compare vs other companies in the TW Biotechs Industry?

0 CompaniesPrice / BookEstimated GrowthMarket Cap
6973 is unprofitableIndustry Avg. 3.9xNo. of Companies7PB02.44.87.29.612+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: Insufficient data to calculate 6973's Price-To-Book Ratio vs. industry for valuation analysis.

Price to Book Ratio vs Fair Ratio

What is 6973's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

6973 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ration/a
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 6973's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

YungShin Global Holding

NT$15.4b

Through its subsidiaries, invests in, manufactures, and sells medicines, animal drugs, agricultural chemicals, industrial medicines, and cosmetics in Taiwan, Mainland China, Japan, and the United States.

3705

NT$57.90

7D

8.2%

1Y

27.1%

Winston Medical Supply

NT$1.6b

Winston Medical Supply Co.,Ltd. develops, manufactures, and distributes pharmaceuticals, nutrition supplements, and cosmeceutical products.

6817

NT$88.30

7D

-1.6%

1Y

-13.4%

RBC Bioscience

NT$254.3m

Researches, develops, manufactures, and sells reagents and devices for life science and molecular diagnosis in Europe, the United States, Asia, Taiwan, Africa, and Australia.

6848

NT$19.60

7D

-0.5%

1Y

29.8%